Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) – Analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for Tonix Pharmaceuticals in a research report issued to clients and investors on Wednesday, September 2nd. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($2.50) per share for the quarter, up from their prior estimate of ($2.63). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($10.03) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q4 2026 earnings at ($2.28) EPS, FY2026 earnings at ($10.03) EPS, FY2027 earnings at ($5.48) EPS and FY2028 earnings at $1.86 EPS.
A number of other equities analysts have also recently issued reports on TNXP. Wall Street Zen raised Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Raymond James Financial reiterated a “strong-buy” rating and issued a $27.00 price target on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings cut Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.50.
Tonix Pharmaceuticals Stock Down 2.5%
Shares of TNXP opened at $12.83 on Thursday. The stock has a market cap of $220.03 million, a price-to-earnings ratio of -0.99 and a beta of 1.74. Tonix Pharmaceuticals has a 12 month low of $9.40 and a 12 month high of $31.55. The company has a 50-day moving average price of $12.13 and a two-hundred day moving average price of $12.87.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.99%. The firm had revenue of $13.54 million for the quarter, compared to analyst estimates of $7.72 million.
Insider Buying and Selling
In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $13.79 per share, with a total value of $27,580.00. Following the acquisition, the chief executive officer directly owned 11,005 shares of the company’s stock, valued at approximately $151,758.95. This trade represents a 22.21% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders purchased 4,415 shares of company stock worth $55,108. 2.00% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Tonix Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of TNXP. Royal Bank of Canada bought a new position in shares of Tonix Pharmaceuticals in the first quarter valued at about $610,000. Geode Capital Management LLC grew its holdings in Tonix Pharmaceuticals by 182.4% during the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after acquiring an additional 113,175 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $129,000. Legal & General Group Plc bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $25,000. Finally, New York State Common Retirement Fund bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $104,000. Institutional investors and hedge funds own 82.26% of the company’s stock.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Recommended Stories
- Five stocks we like better than Tonix Pharmaceuticals
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
